A Pilot Study Using 18F-DOPA PET-guided Radiotherapy in Gliomas
| Status: | Active, not recruiting |
|---|---|
| Conditions: | Brain Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 4/25/2018 |
| Start Date: | April 2014 |
| End Date: | April 2019 |
A Pilot Study Evaluating the Utility of 18F-DOPA PET for Radiotherapy Treatment Planning of Malignant Glioma Patients
For most brain tumors, radiation treatment is guided by a Magnetic Resonance Imaging (MRI)
scan. In this study, information from a special scan, called a Positron Emission Tomography/
Computed Tomography (PET/CT) scan using an amino acid called
Fluorine-18-L-dihydroxyphenylalanine (18F-DOPA) will also be used to image the tumor and
guide your radiation oncologist in determining locations to treat with radiation. This type
of scan has shown promise in being able to better distinguish tumor from normal brain tissue
and may help to more accurately plan radiation treatment. This type of scan can also assist
the radiation oncologist in identifying the most aggressive regions of the tumor. The goal of
this study is to use the 18F-DOPA PET/CT scan to help determine where the disease is that
needs to be treated with radiation, in order to improve the effectiveness of radiation in
this tumor.
scan. In this study, information from a special scan, called a Positron Emission Tomography/
Computed Tomography (PET/CT) scan using an amino acid called
Fluorine-18-L-dihydroxyphenylalanine (18F-DOPA) will also be used to image the tumor and
guide your radiation oncologist in determining locations to treat with radiation. This type
of scan has shown promise in being able to better distinguish tumor from normal brain tissue
and may help to more accurately plan radiation treatment. This type of scan can also assist
the radiation oncologist in identifying the most aggressive regions of the tumor. The goal of
this study is to use the 18F-DOPA PET/CT scan to help determine where the disease is that
needs to be treated with radiation, in order to improve the effectiveness of radiation in
this tumor.
Inclusion Criteria:
- Age ≥18 years.
- Biopsy confirmed newly diagnosed or recurrent WHO Grade II or Grade III malignant
glioma, or Grade III malignant astrocytoma or oligoastrocytoma.
- Planned radiation treatments at Mayo Clinic Rochester.
- Willing to sign release of information for any follow-up records.
- Provide informed written consent.
- Willingness to participate in mandatory pre- and post-treatment imaging studies.
Exclusion Criteria:
- Patients diagnosed with WHO grade III oligodendroglioma or WHO grade IV malignant
glioma.
- Patients previously treated with radiation therapy.
- Unable to undergo MRI scans with contrast (e.g. cardiac pacemaker, defibrillator,
kidney failure).
- Unable to undergo an 18F-DOPA PET scan (e.g. Parkinson's Disease, taking
anti-dopaminergic, or dopamine agonist medication or less than 6 half-lives from
discontinuance of dopamine agonists)
- Pregnant women
- Nursing women
- Men or women of childbearing potential who are unwilling to employ adequate
contraception
We found this trial at
1
site
Rochester, Minnesota 55905
Principal Investigator: Debra H Brinkmann, Ph.D.
Phone: 507-284-7228
Click here to add this to my saved trials
